2 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Mycophenolate: new trials by email Literature Review of Mycophenolate trials Research Report on Mycophenolate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar - Transplant Rejection | Phase 2 | Active not recruiting | Sanofi | 48 | 2022-06-09 | 2026-08-21 |
| Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine - Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis | Phase 2 | Terminated | Washington University School of Medicine | 2 | 2022-02-21 | 2023-11-07 |
| Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging - Leukemia, Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 20 | 2013-01-01 | 2020-05-05 |
| Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant Low Molecular Weight Sulfated Dextran, Heparin, Mycophenolate Mofetil - Diabetes Mellitus, Type I | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2008-07-01 | 2014-06-12 | |
| Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis mycophenolate mofetil, placebo - Systemic Lupus Erythematosus, Arthritis | Phase 1 / Phase 2 | Completed | Oklahoma Medical Research Foundation | 27 | 2006-11-01 | 2020-10-09 |
Lupus Erythematosus, Systemic (2) · Arthritis (1) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Dermatomyositis (1) · Diabetes Mellitus, Type 1 (1) · Giant Cell Arteritis (1) · Granulomatosis with Polyangiitis (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Pemphigoid, Benign Mucous Membrane (1) · Polymyalgia Rheumatica (1)
M.D. Anderson Cancer Center (1) · NYU Langone Health (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Oklahoma Medical Research Foundation (1) · Sanofi (1) · Washington University School of Medicine (1)
United States (5) · Canada (1) · France (1) · Germany (1) · Italy (1) · Spain (1) · Sweden (1)
Issa F. Khouri, MD,BS (1) · Joan T. Merrill, M.D. (1) · Jonathan Samuels, MD (1) · Olle Korsgren, MD (1) · Robert Clancy, PhD (1)
2023 (1)